- Home
- IMMX vs BRSP Comparison
IMMX vs BRSP Comparison
Compare IMMX & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMX | BRSP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 629.3M | 738.7M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IMMX | BRSP |
|---|---|---|
| Price | $8.22 | $5.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $19.20 | $6.50 |
| AVG Volume (30 Days) | ★ 1.4M | 828.0K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.03% |
| EPS Growth | N/A | ★ 75.24 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $330,587,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.54 |
| P/E Ratio | ★ N/A | $185.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.94 | $4.84 |
| 52 Week High | $11.61 | $6.17 |
Technical Indicators
Market Signals| Indicator | IMMX | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 39.60 | 45.95 |
| Support Level | $8.10 | $5.44 |
| Resistance Level | $10.61 | $5.76 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 21.93 | 49.71 |
Price Performance
Historical ComparisonAbout IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.